cevac md hvt suspensão e solvente para suspensão injetável para frangos de carne, futuras poedeiras e futuras reprodutoras
ceva saúde animal - herpesvírus do perú 0.0 - suspensão e diluente para suspensão injetável - herpesvírus aviário (doença de marek) - ovos embrionados*, galinhas
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
avishield ibd int
genera inc. - vacina contra a doença de gumboro (bursite infeciosa) - liofilizado para suspensão - aves de exploração
menjugate 10 µg/0.5 ml+12.5-25 µg/0.5 ml suspensão injetável
gsk vaccines s.r.l. - vacina contra o meningococo - suspensão injetável - 10 µg/0.5 ml+12.5-25 µg/0.5 ml - proteína diftérica crm197 25 µg/ml ; oligossacáridos meningocócicos 20 µg/ml - meningococcal vaccines - n/a - duração do tratamento: curta ou média duração
menjugate 10 µg/0.5 ml+12.5-25 µg/0.5 ml suspensão injetável
gsk vaccines s.r.l. - vacina contra o meningococo - suspensão injetável - 10 µg/0.5 ml+12.5-25 µg/0.5 ml - proteína diftérica crm197 25 µg/ml ; oligossacáridos meningocócicos 20 µg/ml - meningococcal vaccines - n/a - duração do tratamento: curta ou média duração
menjugate 10 µg/0.5 ml+12.5-25 µg/0.5 ml suspensão injetável
gsk vaccines s.r.l. - vacina contra o meningococo - suspensão injetável - 10 µg/0.5 ml+12.5-25 µg/0.5 ml - proteína diftérica crm197 25 µg/ml ; oligossacáridos meningocócicos 20 µg/ml - meningococcal vaccines - n/a - duração do tratamento: curta ou média duração
menjugate 10 µg/0.5 ml+12.5-25 µg/0.5 ml suspensão injetável
gsk vaccines s.r.l. - vacina contra o meningococo - suspensão injetável - 10 µg/0.5 ml+12.5-25 µg/0.5 ml - proteína diftérica crm197 25 µg/ml ; oligossacáridos meningocócicos 20 µg/ml - meningococcal vaccines - n/a - duração do tratamento: curta ou média duração
prehevbri
vbi vaccines b.v. - antígeno de superfície da hepatite b - hepatite b - vacinas - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.
tuberculina ppd rt 23 ssi 0.002 mg/ml solução injetável
aj vaccines a/s - tuberculina - solução injetável - 0.002 mg/ml - tuberculina 0.002 mg/ml - tuberculin - n/a - duração do tratamento: curta ou média duração